Human malaria infections resulting from Plasmodium falciparum have become increasingly difficult to treat due to the emergence of drug-resistant parasites. The P. falciparum purine salvage enzyme purine nucleoside phosphorylase (PfPNP) is a potential drug target. Previous studies, in which PfPNP was targeted by transition state analogue inhibitors, found that those inhibiting human PNP and PfPNPs killed P. falciparum in vitro. However, many drugs have off-target interactions, and genetic evidence is required to demonstrate single target action for this class of potential drugs. We used targeted gene disruption in P. falciparum strain 3D7 to ablate PNP expression, yielding transgenic 3D7 parasites (⌬pfpnp). Lysates of the ⌬pfpnp parasites showed no PNP activity, but activity of another purine salvage enzyme, adenosine deaminase (PfADA), was normal. When compared with wild-type 3D7, the ⌬pfpnp parasites showed a greater requirement for exogenous purines and a severe growth defect at physiological concentrations of hypoxanthine. Drug assays using immucillins, specific transition state inhibitors of PNP, were performed on wild-type and ⌬pfpnp parasites. The ⌬pfpnp parasites were more sensitive to PNP inhibitors that bound hPNP tighter and less sensitive to MT-ImmH, an inhibitor with 100-fold preference for PfPNP over hPNP. The results demonstrate the importance of purine salvage in P. falciparum and validate PfPNP as the target of immucillins.Each year, Plasmodium species infect 300 to 500 million people and cause nearly two million deaths, mostly in children under the age of five in sub-Saharan Africa (1). Most deaths are due to infection with Plasmodium falciparum. Only AIDS and tuberculosis are more lethal human infectious diseases. No vaccine is available, despite intensive international efforts. At present, control of malaria is dependent on prevention with bed nets, insecticides or chemoprophylaxis, and chemotherapeutic treatment of clinical cases. However, chemotherapy for malaria has been complicated by recent increases in mortality and morbidity due to the emergence of drug-resistant strains (2).Because parasitic protozoa are unable to synthesize purines de novo, purine salvage has been proposed as a potential target for chemotherapy of protozoan parasite infections, including those caused by Plasmodium spp. Malaria parasites are obligate intracellular parasites that carry out their asexual cycle in erythrocytes. Unlike most mammalian cells, erythrocytes have no biochemical machinery for de novo purine synthesis, but act as a rich source of purine salvage enzymes, particularly purine nucleoside phosphorylase (PNP) 4 and adenosine deaminase (ADA). The purine salvage pathway of Plasmodium begins with the deamination of adenosine to inosine by ADA, followed by conversion of inosine to hypoxanthine by PNP. The final enzyme in the pathway is hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT). Hypoxanthine is a precursor for all purines and is a central metabolite for nucleic acid synthesis in P. ...